title: Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study.
abstract: BACKGROUND
  Empirical evidence of the efficacy and effectiveness of psychosocial family intervention and of the specificity of its effects on the course of schizophrenia is limited. The aim was to study the efficacy and effectiveness of psychosocial family intervention with regard to clinical and social functioning and family burden after controlling for compliance and several prognostic factors.
  
  
  METHODS
  A 2-year randomized controlled trial with blind assessments. Fifty patients with DSM-IV schizophrenia and persistent positive symptoms and/or previous clinical relapse were allocated to psychosocial family intervention, individual counselling and standard treatment versus individual counselling and standard treatment.
  
  
  RESULTS
  Family intervention was associated with fewer clinical relapses, hospitalizations and major incidents, and an improvement in positive and negative symptoms, social role performance, social relations, employment and family burden. The reduction in hospitalizations in the family intervention group was significantly greater than that observed in the group of patients who refused to participate but this was not the case for the control group. The effects of family intervention were independent of compliance and prognostic factors.
  
  
  CONCLUSIONS
  Family intervention is effective in severe schizophrenia independently of compliance and prognostic factors.
authors.affiliation: Department of Clinical Medicine, University Miguel Hernández, Alacant, Spain. giron@icali.es
authors.forename: M
authors.initials: M
authors.lastname: Girón
authors.forename: A
authors.initials: A
authors.lastname: Fernández-Yañez
authors.forename: S
authors.initials: S
authors.lastname: Mañá-Alvarenga
authors.forename: A
authors.initials: A
authors.lastname: Molina-Habas
authors.forename: A
authors.initials: A
authors.lastname: Nolasco
authors.forename: M
authors.initials: M
authors.lastname: Gómez-Beneyto
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D017028:Caregivers / Q000523:psychology*; D003131:Combined Modality Therapy; D017281:Cost of Illness; D005196:Family Therapy; D005260:Female; D006801:Humans; D008297:Male; D010349:Patient Compliance / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D011613:Psychotherapy; D011618:Psychotic Disorders / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D012559:Schizophrenia / Q000175:diagnosis / Q000628:therapy*; D012565:Schizophrenic Psychology; D055502:Secondary Prevention; D012917:Social Adjustment; D013030:Spain; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents